Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration

INTRODUCTION: Oral administration of zeaxanthin (Zx) 20 mg daily in patients with unilateral neovascular age-related macular degeneration (nAMD) treated with triple therapy (photodynamic therapy/intravitreal bevacizumab/intravitreal dexamethasone) reduced fellow-eye 2-year nAMD incidence from 23 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Gary C., Brown, Melissa M., Gierhart, Dennis, Olk, R. Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441916/
https://www.ncbi.nlm.nih.gov/pubmed/37430077
http://dx.doi.org/10.1007/s40123-023-00742-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441916/
https://www.ncbi.nlm.nih.gov/pubmed/37430077
http://dx.doi.org/10.1007/s40123-023-00742-9

Ejemplares similares